Crystal Rock Capital Management Sells 4,550 Shares of Boston Scientific Corporation $BSX

Crystal Rock Capital Management cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 6.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 64,770 shares of the medical equipment provider’s stock after selling 4,550 shares during the quarter. Boston Scientific comprises approximately 4.0% of Crystal Rock Capital Management’s portfolio, making the stock its 9th largest holding. Crystal Rock Capital Management’s holdings in Boston Scientific were worth $6,957,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. 1248 Management LLC acquired a new position in Boston Scientific in the first quarter valued at $26,000. Y.D. More Investments Ltd acquired a new position in shares of Boston Scientific during the first quarter worth about $27,000. Sound Income Strategies LLC increased its stake in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the period. Princeton Global Asset Management LLC acquired a new position in shares of Boston Scientific during the second quarter worth about $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Boston Scientific during the second quarter worth about $37,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ellen M. Zane sold 2,901 shares of the company’s stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $102.24, for a total transaction of $296,598.24. Following the completion of the sale, the director directly owned 24,134 shares in the company, valued at $2,467,460.16. This trade represents a 10.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 112,891 shares of company stock worth $11,501,887 in the last ninety days. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BSX. Leerink Partners boosted their price target on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Royal Bank Of Canada reiterated an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a research note on Monday, September 29th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Wells Fargo & Company upped their target price on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Finally, BTIG Research restated a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a research report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Trading Up 0.2%

Shares of BSX opened at $100.81 on Friday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The firm’s 50-day moving average is $100.76 and its two-hundred day moving average is $102.35. Boston Scientific Corporation has a twelve month low of $83.38 and a twelve month high of $109.50. The firm has a market capitalization of $149.37 billion, a P/E ratio of 53.91, a PEG ratio of 2.02 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the business posted $0.63 earnings per share. The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.